Drug repurposing is an attractive strategy for extending the arsenal of oncology therapies. Screening of a large collection of existing non-oncology compounds against a panel of cancer cell lines now identifies several drugs capable of selectively inhibiting the growth of cancer cells.
This is a preview of subscription content, log in via an institution to check access.
References
Corsello, S.M.N. Nat. Cancer https://doi.org/10.1038/s43018-019-0018-6 (2019).
Corsello, S. M. et al. Nat. Med. 23, 405–408 (2017).
Yu, C. et al. Nat. Biotechnol. 34, 419–423 (2016).
Garnett, M. J. et al. Nature 483, 570–575 (2012).
Basu, A. et al. Cell 154, 1151–1161 (2013).
Ghandi, M. et al. Nature 569, 503–508 (2019).
Barretina, J. et al. Nature 483, 603–607 (2012).
de Waal, L. et al. Nat. Chem. Biol. 12, 102–108 (2016).
Allensworth, J. L. et al. Mol. Oncol. 9, 1155–1168 (2015).
Peters, K. G. et al. J. Inorg. Biochem. 96, 321–330 (2003).
Clark, O. et al. Cancer Lett. 357, 316–327 (2015).
Argentieri, D. C. et al. J. Pharmacol. Exp. Ther. 271, 1399–1408 (1994).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Beijersbergen, R.L. Old drugs with new tricks. Nat Cancer 1, 153–155 (2020). https://doi.org/10.1038/s43018-020-0024-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-0024-8
- Springer Nature America, Inc.
This article is cited by
-
Continuous Spatiotemporal Therapy of A Full-API Nanodrug via Multi-Step Tandem Endogenous Biosynthesis
Nature Communications (2023)
-
Overcoming cancer therapeutic bottleneck by drug repurposing
Signal Transduction and Targeted Therapy (2020)
-
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis
Scientific Reports (2020)